CLL16Recruiting

New Triple-Drug Combination Therapy with Acalabrutinib, Obinutuzumab, and Venetoclax for Untreated High-Risk Chronic Lymphocytic Leukemia

Gender
Women and men
Age
18 years and older
Trial type
Interventional
Line of therapy
First line
Phase
Phase III

What is this trial about?

and are malignant diseases of the blood and . Treatment is based on the presence of certain risk factors. Acalabrutinib is a new drug that has already been approved for the treatment of CLL, but not as part of a triple combination as for high-risk patients. The goal of the CLL16 study is to investigate the efficacy of combination therapy with acalabrutinib, , and compared to the combination of obinutuzumab and venetoclax. Patients aged 18 and older with CLL or SLL are eligible to participate in this study if they have a high-risk factor (, TP53 , or complex karyotype).

Detailed description

Chronic lymphocytic leukemia (CLL) is a type of blood cancer characterized by the uncontrolled proliferation of in the bone marrow. are a type of white blood cell that is part of the immune system. In CLL, the lymphocytes are released into the bloodstream. If, instead, the lymphocytes are found primarily in the lymph nodes and the spleen, the condition is referred to as small-cell lymphocytic (SLL), which is grouped together with CLL under a single clinical classification. CLL is a type of ; it typically grows slowly and occurs primarily in older adults. The causes of CLL are not yet fully understood, but genetic factors play a role (this refers to acquired genetic changes in the cancer cells, not inheritance from parents to a child). Treatment depends on the severity of the symptoms and the patient’s overall physical condition. If patients show no symptoms, treatment is generally not initiated; instead, regular monitoring (“watch and wait”) is performed. In cases of symptomatic disease, depends on the presence of certain risk factors, which are determined by genetic testing of the affected cells. Typically, a combination of and chemotherapy is used as first-line therapy.

If specific genetic alterations are detected (17p deletion, TP53 mutation, or complex karyotype), the disease is classified as high-risk CLL. This requires a tailored approach to treatment selection. The standard treatment in these cases is immunotherapy, for example with the new drug acalabrutinib or obinutuzumab plus venetoclax. There are various treatment regimens and combination options for these drugs. The combination of acalabrutinib, venetoclax, and obinutuzumab has not yet been established, although all three drugs are approved for the treatment of CLL/SLL.  Acalabrutinib is a so-called Bruton’s (BTK inhibitor), which inhibits the proliferation of cancer cells. Venetoclax is a so-called , and obinutuzumab is an antibody that targets the surface receptor on B lymphocytes. All of these drugs directly or indirectly induce the death of cancer cells.

The goal of this Phase 3 study is to investigate the efficacy and safety of the combination immunotherapy of acalabrutinib, venetoclax, and obinutuzumab in a larger number of patients. The treatment is administered as first-line therapy; therefore, the patients have not yet received any prior treatment. As part of the study, patients are randomly assigned to two groups. Group 1 receives the combination immunotherapy consisting of acalabrutinib, venetoclax, and obinutuzumab for up to 24 of 28 days each, although not all medications are administered in every cycle. Group 2 receives a combination therapy consisting of venetoclax and obinutuzumab over 12 cycles. The study is open-label, meaning that both the medical staff and the patient know which medications are being administered. Treatments and visits as part of the study will continue for up to 50 months, during which the effectiveness of the therapy and the occurrence of side effects from the various medications will be evaluated. The key factor is whether or when the disease progresses again during therapy (). The of the study is the survival rate without disease progression for up to 50 months after treatment of the first participant.

Patients aged 18 and older with CLL or SLL are eligible to participate in this study. The disease must not have been previously treated and must have at least one high-risk genetic factor (17p deletion, TP53 mutation, complex karyotype).

Facts

  1. Disease: , .
  2. Cancer characteristics: untreated, high-risk status (, TP53 , complex karyotype).
  3. What the study investigates: Efficacy and safety of combination therapy with acalabrutinib, , and compared to obinutuzumab/venetoclax.
  4. Study objective: To improve .
  5. Study duration: for up to 50 months.
  6. Study characteristics: Phase 3 study, two treatment arms, , open-label; all drugs used are already approved, but the triple combination in this form is not.

Trial sites

93 trial sites in Germany are listed. Find a site near you.

  • Klinikum St. Marien Amberg

    Mariahilfbergweg 7, 92224 Amberg

    Recruiting
  • Klinikum Aschaffenburg-Alzenau gemeinnützige GmbH

    Am Hasenkopf 1, 63739 Aschaffenburg

    Status unknown
  • Haematologie-Onkologie im Zentrum MVZ GmbH

    Halderstrasse 29, 86150 Augsburg

    Status unknown
  • HELIOS Klinikum Bad Saarow

    Pieskower Strasse 33, 15526 Bad Saarow

    Recruiting
  • Klinikum Mittelbaden Baden-Baden Bühl

    Balger Str. 50, 76532 Baden-Baden

    Status unknown
  • Charité – Universitätsmedizin Berlin

    Berlin

    Recruiting

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time. Last checked against the trial registers on .

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry entry and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.